Biomarker Analysis of the Phase 3 KEYNOTE-426 Study of Pembrolizumab (P) Plus Axitinib (A) Versus Sunitinib (S) for Advanced Renal Cell Carcinoma (RCC).
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined